Treatment of acquired severe aplastic anemia: Bone marrow transplantation compared with immunosuppressive therapy - The European Group for blood and marrow transplantation experience

Andrea Bacigalupo, Ronald Brand, Rosi Oneto, Barbara Bruno, Gerard Socié, Jakob Passweg, Anna Locasciulli, Maria Teresa Van Lint, André Tichelli, Shaun McCann, Judith Marsh, Per Ljungman, Jill Hows, Pedro Marin, Hubert Schrezenmeier

Research output: Contribution to journalArticle

Abstract

Patients with severe aplastic anemia (SAA) can be successfully treated with bone marrow transplantation (BMT) or immunosuppressive therapy (IS). The current outcome using both forms of therapy among 3,669 patients treated in Europe between 1976 and 1998 is reviewed. Significant progress has been made and the overall risk of failure is now low, with survival rates greater than 80% for both treatments. Chronic graft-versus-host disease (GvHD) remains a problem for BMT patients, and carries a high risk of lethal complications. On the other hand, IS patients are exposed to late failure due to relapse or clonal/malignant diseases. First-line BMT from identical siblings is compared with IS therapy in an intent-to-treat analysis of 1,765 patients, regardless of subsequent transplant status. The outcome of SAA patients has improved considerably over time and is influenced by patient variables such as severity of the disease and age, but also by the choice of the Initial treatment. Copyright (C) 2000 by W.B. Saunders Company.

Original languageEnglish
Pages (from-to)69-80
Number of pages12
JournalSeminars in Hematology
Volume37
Issue number1
Publication statusPublished - Jan 2000

Fingerprint

Aplastic Anemia
Immunosuppressive Agents
Blood Group Antigens
Bone Marrow Transplantation
Transplantation
Bone Marrow
Therapeutics
Graft vs Host Disease
Siblings
Survival Rate
Transplants
Recurrence

ASJC Scopus subject areas

  • Hematology

Cite this

Treatment of acquired severe aplastic anemia : Bone marrow transplantation compared with immunosuppressive therapy - The European Group for blood and marrow transplantation experience. / Bacigalupo, Andrea; Brand, Ronald; Oneto, Rosi; Bruno, Barbara; Socié, Gerard; Passweg, Jakob; Locasciulli, Anna; Van Lint, Maria Teresa; Tichelli, André; McCann, Shaun; Marsh, Judith; Ljungman, Per; Hows, Jill; Marin, Pedro; Schrezenmeier, Hubert.

In: Seminars in Hematology, Vol. 37, No. 1, 01.2000, p. 69-80.

Research output: Contribution to journalArticle

Bacigalupo, A, Brand, R, Oneto, R, Bruno, B, Socié, G, Passweg, J, Locasciulli, A, Van Lint, MT, Tichelli, A, McCann, S, Marsh, J, Ljungman, P, Hows, J, Marin, P & Schrezenmeier, H 2000, 'Treatment of acquired severe aplastic anemia: Bone marrow transplantation compared with immunosuppressive therapy - The European Group for blood and marrow transplantation experience', Seminars in Hematology, vol. 37, no. 1, pp. 69-80.
Bacigalupo, Andrea ; Brand, Ronald ; Oneto, Rosi ; Bruno, Barbara ; Socié, Gerard ; Passweg, Jakob ; Locasciulli, Anna ; Van Lint, Maria Teresa ; Tichelli, André ; McCann, Shaun ; Marsh, Judith ; Ljungman, Per ; Hows, Jill ; Marin, Pedro ; Schrezenmeier, Hubert. / Treatment of acquired severe aplastic anemia : Bone marrow transplantation compared with immunosuppressive therapy - The European Group for blood and marrow transplantation experience. In: Seminars in Hematology. 2000 ; Vol. 37, No. 1. pp. 69-80.
@article{9d6526e25555456c9a1c425c63b3bcaa,
title = "Treatment of acquired severe aplastic anemia: Bone marrow transplantation compared with immunosuppressive therapy - The European Group for blood and marrow transplantation experience",
abstract = "Patients with severe aplastic anemia (SAA) can be successfully treated with bone marrow transplantation (BMT) or immunosuppressive therapy (IS). The current outcome using both forms of therapy among 3,669 patients treated in Europe between 1976 and 1998 is reviewed. Significant progress has been made and the overall risk of failure is now low, with survival rates greater than 80{\%} for both treatments. Chronic graft-versus-host disease (GvHD) remains a problem for BMT patients, and carries a high risk of lethal complications. On the other hand, IS patients are exposed to late failure due to relapse or clonal/malignant diseases. First-line BMT from identical siblings is compared with IS therapy in an intent-to-treat analysis of 1,765 patients, regardless of subsequent transplant status. The outcome of SAA patients has improved considerably over time and is influenced by patient variables such as severity of the disease and age, but also by the choice of the Initial treatment. Copyright (C) 2000 by W.B. Saunders Company.",
author = "Andrea Bacigalupo and Ronald Brand and Rosi Oneto and Barbara Bruno and Gerard Soci{\'e} and Jakob Passweg and Anna Locasciulli and {Van Lint}, {Maria Teresa} and Andr{\'e} Tichelli and Shaun McCann and Judith Marsh and Per Ljungman and Jill Hows and Pedro Marin and Hubert Schrezenmeier",
year = "2000",
month = "1",
language = "English",
volume = "37",
pages = "69--80",
journal = "Seminars in Hematology",
issn = "0037-1963",
publisher = "W.B. Saunders Ltd",
number = "1",

}

TY - JOUR

T1 - Treatment of acquired severe aplastic anemia

T2 - Bone marrow transplantation compared with immunosuppressive therapy - The European Group for blood and marrow transplantation experience

AU - Bacigalupo, Andrea

AU - Brand, Ronald

AU - Oneto, Rosi

AU - Bruno, Barbara

AU - Socié, Gerard

AU - Passweg, Jakob

AU - Locasciulli, Anna

AU - Van Lint, Maria Teresa

AU - Tichelli, André

AU - McCann, Shaun

AU - Marsh, Judith

AU - Ljungman, Per

AU - Hows, Jill

AU - Marin, Pedro

AU - Schrezenmeier, Hubert

PY - 2000/1

Y1 - 2000/1

N2 - Patients with severe aplastic anemia (SAA) can be successfully treated with bone marrow transplantation (BMT) or immunosuppressive therapy (IS). The current outcome using both forms of therapy among 3,669 patients treated in Europe between 1976 and 1998 is reviewed. Significant progress has been made and the overall risk of failure is now low, with survival rates greater than 80% for both treatments. Chronic graft-versus-host disease (GvHD) remains a problem for BMT patients, and carries a high risk of lethal complications. On the other hand, IS patients are exposed to late failure due to relapse or clonal/malignant diseases. First-line BMT from identical siblings is compared with IS therapy in an intent-to-treat analysis of 1,765 patients, regardless of subsequent transplant status. The outcome of SAA patients has improved considerably over time and is influenced by patient variables such as severity of the disease and age, but also by the choice of the Initial treatment. Copyright (C) 2000 by W.B. Saunders Company.

AB - Patients with severe aplastic anemia (SAA) can be successfully treated with bone marrow transplantation (BMT) or immunosuppressive therapy (IS). The current outcome using both forms of therapy among 3,669 patients treated in Europe between 1976 and 1998 is reviewed. Significant progress has been made and the overall risk of failure is now low, with survival rates greater than 80% for both treatments. Chronic graft-versus-host disease (GvHD) remains a problem for BMT patients, and carries a high risk of lethal complications. On the other hand, IS patients are exposed to late failure due to relapse or clonal/malignant diseases. First-line BMT from identical siblings is compared with IS therapy in an intent-to-treat analysis of 1,765 patients, regardless of subsequent transplant status. The outcome of SAA patients has improved considerably over time and is influenced by patient variables such as severity of the disease and age, but also by the choice of the Initial treatment. Copyright (C) 2000 by W.B. Saunders Company.

UR - http://www.scopus.com/inward/record.url?scp=12944332070&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=12944332070&partnerID=8YFLogxK

M3 - Article

C2 - 10676912

AN - SCOPUS:12944332070

VL - 37

SP - 69

EP - 80

JO - Seminars in Hematology

JF - Seminars in Hematology

SN - 0037-1963

IS - 1

ER -